<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916483</url>
  </required_header>
  <id_info>
    <org_study_id>IRB1081209-04</org_study_id>
    <nct_id>NCT04916483</nct_id>
  </id_info>
  <brief_title>Exploring the Effectiveness of Group Cognitive Stimulation Therapy in People With Schizophrenia.</brief_title>
  <official_title>Exploring the Effectiveness of Group Cognitive Stimulation Therapy on Cognitive Function, Depressive Symptoms, Social Function and Quality of Life in People With Schizophrenia: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Yang Ming University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Yang Ming University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Cognitive dysfunction is the core defect of schizophrenia, which seriously&#xD;
      affects the emotional, social functions and quality of life in people with schizophrenia.&#xD;
&#xD;
      Objective: The purpose of this study is to explore the efficacy of group cognitive&#xD;
      stimulation therapy in cognitive function, depressive symptoms, social function, and quality&#xD;
      of life in people with Schizophrenia.&#xD;
&#xD;
      Research method:This study used a single-blind randomized controlled trial design.&#xD;
      Participants's Montreal Cognitive Assessment Scale (MoCA) score between 10-25 points are&#xD;
      include. Chronic rehabilitation wards were randomly assigned to the experimental group and&#xD;
      the conventional treatment group using blocking. The experimental group (EG) (n = 45) is&#xD;
      receive 7 weeks, twice a week, 60 minutes each time of group cognitive stimulation&#xD;
      therapy(GCST), the control group (CG) (n = 45) maintain usual care.&#xD;
&#xD;
      Expected results: GCST can improve cognitive function, depressive symptoms, social function&#xD;
      and quality of life in people with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Cognitive dysfunction is the core defect of schizophrenia, which seriously&#xD;
      affects the emotional and social functions of patients. Group cognitive stimulation therapy&#xD;
      has been supported by research abroad to improve cognition and mood. Domestically, this group&#xD;
      of people with schizophrenia will also face the above symptoms. Therefore,&#xD;
      non-pharmacological therapy is among mental health personnel It is worth paying attention to&#xD;
      and developing in the process of providing medical services.&#xD;
&#xD;
      Objective: The purpose of this study explores the efficacy of group cognitive stimulation&#xD;
      therapy in cognitive function, depressive symptoms, social function and quality of life in&#xD;
      people with Schizophrenia.&#xD;
&#xD;
      Research method: This study used a single-blind randomized controlled trial design to reduce&#xD;
      it to people with schizophrenia.This study used a single-blind randomized controlled trial&#xD;
      design. Participants's Montreal Cognitive Assessment Scale (MoCA) score between 10-25 points&#xD;
      are include. Chronic rehabilitation wards were randomly assigned to the EG and the CG using&#xD;
      blocking. The EG receive 7 weeks, twice a week, 60 minutes each time of GCST, the CG maintain&#xD;
      usual care. Both groups use the Montreal Cognitive Assessment Scale (MoCA), the Taiwanese&#xD;
      Version of Frontal Assessment Battery (TFAB), the Beck Depression Inventory II (Beck&#xD;
      Depression Inventory II, BDI-II), and Social Function Scales-Taiwanese version(SFST) and&#xD;
      WHOQOL-BREF is use as an evaluation tool to measure the results at the baseline, T1 (7th&#xD;
      weeks) and T2 (20th weeks). The research results were filed and statistically analyzed with&#xD;
      IBM SPSS 20.0 software package. Descriptive statistics were used for general demographic&#xD;
      variables and primary , secondary outcome: mean, SD, range, percentage. The difference&#xD;
      between the two groups of benchmark values was analyzed with t-test or Ï‡2, independent-t&#xD;
      test, pair-t, and GEE.&#xD;
&#xD;
      Expected results: GCST can improve cognitive function, depressive symptoms, social function&#xD;
      and quality of life in people with schizophrenia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants were divided into experimental group and control group through block randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
    <masking_description>The questionnaire is distributed and applied by another researcher (non-investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment, MoCA</measure>
    <time_frame>baseline</time_frame>
    <description>Cognitive function test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Taiwanese Version of Frontal Assessment Battery, TFAB</measure>
    <time_frame>baseline</time_frame>
    <description>Cognitive function test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Memory Scale-Third Edition, WMS-III</measure>
    <time_frame>baseline</time_frame>
    <description>Cognitive function test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II, BDI-II</measure>
    <time_frame>baseline</time_frame>
    <description>Depressive symptoms test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Function Scales-Taiwanese version, SFST</measure>
    <time_frame>baseline</time_frame>
    <description>Social Function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHOQOL-BREF</measure>
    <time_frame>baseline</time_frame>
    <description>quality of life test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment, MoCA</measure>
    <time_frame>7th weeks</time_frame>
    <description>Cognitive function test</description>
  </other_outcome>
  <other_outcome>
    <measure>Taiwanese Version of Frontal Assessment Battery, TFAB</measure>
    <time_frame>7th weeks</time_frame>
    <description>Cognitive function test</description>
  </other_outcome>
  <other_outcome>
    <measure>Wechsler Memory Scale-Third Edition, WMS-III</measure>
    <time_frame>7th weeks</time_frame>
    <description>Cognitive function test</description>
  </other_outcome>
  <other_outcome>
    <measure>Beck Depression Inventory II, BDI-II</measure>
    <time_frame>7th weeks</time_frame>
    <description>Depressive symptoms test</description>
  </other_outcome>
  <other_outcome>
    <measure>Social Function Scales-Taiwanese version, SFST</measure>
    <time_frame>7th weeks</time_frame>
    <description>Social Function test</description>
  </other_outcome>
  <other_outcome>
    <measure>WHOQOL-BREF</measure>
    <time_frame>7th weeks</time_frame>
    <description>quality of life test</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment, MoCA</measure>
    <time_frame>20th week</time_frame>
    <description>Cognitive function test</description>
  </other_outcome>
  <other_outcome>
    <measure>Taiwanese Version of Frontal Assessment Battery, TFAB</measure>
    <time_frame>20th week</time_frame>
    <description>Cognitive function test</description>
  </other_outcome>
  <other_outcome>
    <measure>Wechsler Memory Scale-Third Edition, WMS-III</measure>
    <time_frame>20th week</time_frame>
    <description>Wechsler Memory Scale-Third Edition, WMS-III</description>
  </other_outcome>
  <other_outcome>
    <measure>Beck Depression Inventory II, BDI-II</measure>
    <time_frame>20th week</time_frame>
    <description>Depressive symptoms test</description>
  </other_outcome>
  <other_outcome>
    <measure>Social Function Scales-Taiwanese version, SFST</measure>
    <time_frame>20th week</time_frame>
    <description>Social Function test</description>
  </other_outcome>
  <other_outcome>
    <measure>WHOQOL-BREF</measure>
    <time_frame>20th week</time_frame>
    <description>quality of life test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cognitive Therapy</condition>
  <arm_group>
    <arm_group_label>Exploring the effectiveness of GCST in people with schizophrenia.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group maintains the usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>group cognitive stimulation therapy</intervention_name>
    <description>The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).</description>
    <arm_group_label>Exploring the effectiveness of GCST in people with schizophrenia.</arm_group_label>
    <other_name>GCST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual care</intervention_name>
    <description>The control group maintains the unit routine treatment.</description>
    <arm_group_label>Exploring the effectiveness of GCST in people with schizophrenia.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. People who according the DSM-5 diagnosis of schizophrenia spectrum and have been sick&#xD;
             for more than two years.&#xD;
&#xD;
          2. Age between 20 and 65 years old.&#xD;
&#xD;
          3. There are currently rules for receiving antipsychotics treatment.&#xD;
&#xD;
          4. Regardless of whether you take antidepressants or not.&#xD;
&#xD;
          5. Can communicate clearly in Mandarin and Taiwanese.&#xD;
&#xD;
          6. Those with a score of 10-25 on the Montreal Cognitive Assessment Scale (MoCA).&#xD;
&#xD;
          7. Those who are willing to participate in this study and complete the subject consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. According to DSM-5 criteria, suspected bipolar disorder, anxiety disorder, obsessive-&#xD;
             compulsive disorder, cognitive impairment, substance use disorders, and other&#xD;
             unthinking disorders are exclusion.&#xD;
&#xD;
          2. Have been in or out of the acute ward within three months and currently have suicidal&#xD;
             attempts or violence.&#xD;
&#xD;
          3. Those who are receiving individual or group cognitive behavior therapy.&#xD;
&#xD;
          4. People with intellectual disabilities.&#xD;
&#xD;
          5. Those who are unable to conduct research due to visual or hearing impairment.&#xD;
&#xD;
          6. People who are accepting other clinical trials.&#xD;
&#xD;
          7. Those who have no intention to participate in this study or are unable to complete the&#xD;
             subject's consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiu-Yueh Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Yang-Ming Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chia-Chi Chang, MSN</last_name>
    <phone>886-3-211-8999</phone>
    <phone_ext>3317</phone_ext>
    <email>ccchang@mail.cgust.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chiu-Yueh Yang, PhD</last_name>
    <phone>886-2-2826</phone>
    <phone_ext>7388</phone_ext>
    <email>cyyang3@ym.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Yang-Ming Jiaotong University</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Chiu Yueh, PhD</last_name>
      <phone>02-28267388</phone>
      <email>cyyang3@ym.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Yang Ming University</investigator_affiliation>
    <investigator_full_name>Chiu-Yueh Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cognitive stimulation therapy</keyword>
  <keyword>depressive symptoms</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>social function</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 17, 2021</submitted>
    <returned>November 15, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

